Nutritional value of dried fermentation biomass, hydrolyzed porcine intestinal mucosa products, and fish meal fed to weanling pigs.

Dried fermentation biomass (DFB) and hydrolyzed porcine intestinal mucosa are co-products of L-Lys • HCl production and heparin extraction, respectively. Three experiments were conducted to determine standardized ileal digestibility (SID) of AA (Exp. 1), concentration of DE and ME (Exp. 2), and standardized total tract digestibility (STTD) of P (Exp. 3) in DFB and 2 hydrolyzed porcine intestinal mucosa products (PEP50 and PEP2+), and compare these values with values for fish meal. In Exp. 1, 12 ileal cannulated barrows (BW = 11.5 ± 1.1 kg) were allotted to a replicated 6 × 6 Latin square design with 6 diets and 6 periods. A N-free diet, diet based on soybean meal (SBM), and 4 diets based on a combination of SBM and DFB, PEP50, PEP2+, or fish meal were formulated. With the exception of Lys, there were no differences in SID of indispensable AA between DFB and fish meal. Except for Thr, no differences in SID of indispensable AA between PEP50 and fish meal were observed, but SID of all indispensable AA, except Lys and Trp, was less (P < 0.05) in PEP2+ than in the other ingredients. In Exp. 2, 40 barrows (BW = 12.8 ± 1.4 kg) were allotted to 5 diets with 8 pigs/diet. A basal diet containing 96.4% corn and 4 diets containing corn and DFB, PEP50, PEP2+, or fish meal were formulated. The DE (5,445 kcal/kg DM) and ME (5,236 kcal/kg DM) in DFB were greater (P < 0.01) than in PEP50 (4,758 and 4,512 kcal/kg DM for DE and ME, respectively) and fish meal (4,227 and 3,960 kcal/kg DM for DE and ME, respectively). Also, DE in DFB was greater (P < 0.01) than in PEP2+ (4,935 kcal/kg DM), but ME in DFB was not different from that in PEP2+ (4,617 kcal/kg DM). Furthermore, DE in PEP50 and PEP2+ were greater (P < 0.01) than in fish meal, but ME did not differ from that in fish meal. In Exp. 3, 40 barrows (BW = 12.4 ± 1.3 kg) were randomly allotted to 5 diets with 8 pigs/diet. A P-free diet and 4 diets in which the sole source of P was from DFB, PEP50, PEP2+, or fish meal were formulated. The STTD of P in DFB (96.9%) and PEP2+ (97.6%) were greater (P < 0.01) than in PEP50 and fish meal (76.2% and 68.5%, respectively), and STTD of P in PEP50 was greater (P < 0.01) than in fish meal. In summary, SID of most indispensable AA did not differ among DFB, PEP50, and fish meal, but DE and ME and STTD of P in DFB were greater than in PEP50 and fish meal.

Factors affecting storage stability of various commercial phytase sources.

A 360-d study was performed to evaluate the effects of different environmental conditions on storage stability of exogenous phytases. Coated and uncoated products from 3 phytase sources [Ronozyme P (DSM Nutritional Products, Basel, Switzerland), OptiPhos (Phytex LLC, Sheridan, IN), and Phyzyme (Danisco Animal Nutrition, Marlborough, UK)] were stored as pure forms, in a vitamin premix, or in a vitamin and trace mineral (VTM) premix. Pure products were stored at -18, 5, 23, and 37°C (75% humidity). Premixes were stored at 23 and 37°C. Sampling was performed on d 0, 30, 60, 90, 120, 180, 270, and 360. Sampling of the pure products stored at -18 (lack of sample) and 5°C (because of mold growth) was discontinued after d 120. Stability was reported as the residual phytase activity (% of initial) at each sampling point. For the stability of the pure forms, all interactive and main effects of the phytase product, coating, time, and storage temperature were significant (P < 0.01), except for the time × coating interaction. When stored at 23°C or less, pure phytases retained at least 91, 85, 78, and 71% of their initial phytase activity at 30, 60, 90, and 120 d of storage, respectively. However, storing pure products at 37°C reduced (P < 0.01) phytase stability, with OptiPhos retaining the most (P < 0.01) activity. Coating mitigated (P < 0.01) the negative effects of high storage temperature for Ronozyme and OptiPhos (from d 90 onward), but not for Phyzyme. For the stability of phytase in different forms of storage, all interactive and main effects of phytase product, form, coating, time, and temperature of storage were significant (P < 0.01). When stored at room temperature (23°C), retained phytase activities for most the phytase sources were more than 85, 73, and 60% of the initial activity up to 180 d when stored as pure products, vitamin premixes, or VTM premixes, respectively. When stored at 37°C, pure phytase products had greater (P < 0.01) retention of initial phytase activity than when phytases were mixed with the vitamin or VTM premixes. Coated phytases stored in any form had greater (P < 0.01) activity retention than the uncoated phytases at all sampling periods. Results indicate that storage stability of commercially available phytases is affected by duration of storage, temperature, product form, coating, and phytase source. Pure products held at 23°C or less were the most stable. In premixes, longer storage times and higher temperatures reduced phytase activity, but coating mitigated some of these negative effects.

Efficacy of different commercial phytase enzymes and development of an available phosphorus release curve for Escherichia coli-derived phytases in nursery pigs.

In 2 experiments, a total of 184 pigs (PIC, initial BW of 10.3 and 9.7 kg for Exp. 1 and 2, respectively) were used to develop an available P (aP) release curve for commercially available Escherichia coli-derived phytases. In both experiments, pigs were fed a corn-soybean meal basal diet (0.06% aP) and 2 diets with added inorganic P (iP) from monocalcium phosphate (Exp. 1: 0.075 and 0.15% aP; Exp. 2: 0.07 and 0.14% aP) to develop a standard curve. In Exp. 1, 100, 175, 250, or 500 phytase units (FTU)/kg of OptiPhos 2000 or 200, 350, 500, or 1,000 FTU/kg of Phyzyme XP were added to the basal diet. In Exp. 2, 250, 500, 750, or 1,000 FTU/kg of OptiPhos 2000; 500, 1,000, or 1,500 FTU/kg of Phyzyme XP; or 1,850 or 3,700 FTU/kg of Ronozyme P were added to the basal diet. One FTU was defined as the amount of enzyme required to release 1 µmol of iP per minute from sodium phytate at 37°C. For all phytase products, the manufacturer-guaranteed phytase activities were used in diet formulation. All diets were analyzed for phytase activity using both the Phytex and AOAC methods. Pigs were blocked by sex and BW and allotted to individual pens with 8 pens per treatment. Pigs were killed on d 21, and fibulas were collected and analyzed for bone ash. In both experiments, increasing iP improved (linear, P < 0.01) G:F and percentage bone ash. Pigs fed increasing OptiPhos had improved (Exp. 1: linear, P < 0.001; Exp. 2: quadratic, P < 0.001) percentage bone ash, as did pigs fed increasing Phyzyme XP (linear, P < 0.001). In Exp. 2, increasing Ronozyme P improved (quadratic, P < 0.01) percentage bone ash. Using analyzed values from the AOAC method and percentage bone ash as the response variable, an aP release curve was developed for up to 1,000 FTU/kg of E. coli-derived phytases (OptiPhos 2000 and Phyzyme XP) in P-deficient diets. The prediction equation was Y = -0.000000125X(2) + 0.000236X + 0.016, where Y = aP release (%) and X = analyzed phytase (FTU/kg) in the diet.

Endothelial progenitors encapsulated in bioartificial niches are insulated from systemic cytotoxicity and are angiogenesis competent.

Intrinsic stem cells (SC) participate in tissue remodeling and regeneration in various diseases and following toxic insults. Failure of tissue regeneration is in part attributed to lack of SC protection from toxic stress of noxious stimuli, thus prompting intense research efforts to develop strategies for SC protection and functional preservation for in vivo delivery. One strategy is creation of artificial SC niches in an attempt to mimic the requirements of endogenous SC niches by generating scaffolds with properties of extracellular matrix. Here, we investigated the use of hyaluronic acid (HA) hydrogels as an artificial SC niche and examined regenerative capabilities of encapsulated embryonic endothelial progenitor cells (eEPC) in three different in vivo models. Hydrogel-encapsulated eEPC demonstrated improved resistance to toxic insult (adriamycin) in vitro, thus prompting in vivo studies. Implantation of HA hydrogels containing eEPC to mice with adriamycin nephropathy or renal ischemia resulted in eEPC mobilization to injured kidneys (and to a lesser extent to the spleen) and improvement of renal function, which was equal or superior to adoptively transferred EPC by intravenous infusion. In mice with hindlimb ischemia, EPC encapsulated in HA hydrogels dramatically accelerated the recovery of collateral circulation with the efficacy superior to intravenous infusion of EPC. In conclusion, HA hydrogels protect eEPC against adriamycin cytotoxicity and implantation of eEPC encapsulated in HA hydrogels supports renal regeneration in ischemic and cytotoxic (adriamycin) nephropathy and neovascularization of ischemic hindlimb, thus establishing their functional competence and superior capabilities to deliver stem cells stored in and released from this bioartificial niche.

Modeling the rovibrationally excited C2H4OH radicals from the photodissociation of 2-bromoethanol at 193 nm.

This study photolytically generates, from 2-bromoethanol photodissociation, the 2-hydroxyethyl radical intermediate of the OH + ethene reaction and measures the velocity distribution of the stable radicals. We introduce an impulsive model to characterize the partitioning of internal energy in the C(2)H(4)OH fragment. It accounts for zero-point and thermal vibrational motion to determine the vibrational energy distribution of the nascent C(2)H(4)OH radicals and the distribution of total angular momentum, J, as a function of the total recoil kinetic energy imparted in the photodissociation. We render this system useful for the study of the subsequent dissociation of the 2-hydroxyethyl radical to the possible asymptotic channels of the OH + ethene reaction. The competition between these channels depends on the internal energy and the J distribution of the radicals. First, we use velocity map imaging to separately resolve the C(2)H(4)OH + Br((2)P(3/2)) and C(2)H(4)OH + Br((2)P(1/2)) photodissociation channels, allowing us to account for the 10.54 kcal/mol partitioned to the Br((2)P(1/2)) cofragment. We determine an improved resonance enhanced multiphoton ionization (REMPI) line strength for the Br transitions at 233.681 nm (5p (4)P(1/2) <-- 4p (2)P(3/2)) and 234.021 nm (5p (2)S(1/2) <-- 4p (2)P(1/2)) and obtain a spin-orbit branching ratio for Br((2)P(1/2)):Br((2)P(3/2)) of 0.26 +/- 0.03:1. Energy and momentum conservation give the distribution of total internal energy, rotational and vibrational, in the C(2)H(4)OH radicals. Then, using 10.5 eV photoionization, we measure the velocity distribution of the radicals that are stable to subsequent dissociation. The onset of dissociation occurs at internal energies much higher than those predicted by theoretical methods and reflects the significant amount of rotational energy imparted to the C(2)H(4)OH photofragment. Instead of estimating the mean rotational energy with an impulsive model from the equilibrium geometry of 2-bromoethanol, our model explicitly includes weighting over geometries across the quantum wave function with zero, one, and two quanta in the harmonic mode that most strongly alters the exit impact parameter. The model gives a nearly perfect prediction of the measured velocity distribution of stable radicals near the dissociation onset using a G4 prediction of the C-Br bond energy and the dissociation barrier for the OH + ethene channel calculated by Senosiain et al. (J. Phys. Chem. A 2006, 110, 6960). The model also indicates that the excited state dissociation proceeds primarily from a conformer of 2-bromoethanol that is trans across the C-C bond. We discuss the possible extensions of our model and the effect of the radical intermediate's J-distribution on the branching between the OH + ethene product channels.

Postobstructive regeneration of kidney is derailed when surge in renal stem cells during course of unilateral ureteral obstruction is halted.

Unilateral ureteral obstruction (UUO), a model of tubulointerstitial scarring (TIS), has a propensity toward regeneration of renal parenchyma after release of obstruction (RUUO). No information exists on the contribution of stem cells to this process. We performed UUO in FVB/N mice, reversed it after 10 days, and examined kidneys 3 wk after RUUO. UUO resulted in attenuation of renal parenchyma. FACS analysis of endothelial progenitor (EPC), mesenchymal stem (MSC) and hematopoietic stem (HSC) cells obtained from UUO kidneys by collagenase-dispersed single-cell suspension showed significant increase in EPC, MSC, and HSC compared with control. After RUUO cortical parenchyma was nearly restored, and TIS score improved by 3 wk. This reversal process was associated with return of stem cells toward baseline level. When animals were chronically treated with nitric oxide synthase (NOS) inhibitor at a dose that did not induce hypertension but resulted in endothelial dysfunction, TIS scores were not different from control UUO, but EPC number in the kidney decreased significantly; however, parenchymal regeneration in these mice was similar to control. Blockade of CXCR4-mediated engraftment resulted in dramatic worsening of UUO and RUUO. Similar results were obtained in caveolin-1-deficient but not -overexpressing mice, reflecting the fact that activation of CXCR4 occurs in caveolae. The present data show increase in EPC, HSC, and MSC population during UUO and a tendency for these cells to decrease to control level during RUUO. These processes are minimally affected by chronic NOS inhibition. Blockade of CXCR4-stromal cell-derived factor-1 (SDF-1) interaction by AMD3100 or caveolin-1 deficiency significantly reduced the UUO-associated surge in stem cells and prevented parenchymal regeneration after RUUO. We conclude that the surge in stem cell accumulation during UUO is a prerequisite for regeneration of renal parenchyma.

Estimation of the true ileal digestible lysine and sulfur amino acid requirement and comparison of the bioefficacy of 2-hydroxy-4-(methylthio)butanoic acid and DL-methionine in eleven- to twenty-six-kilogram nursery pigs.

Three experiments were conducted to determine the true ileal digestible (TID) Lys and sulfur AA (SAA) requirement and to compare the bioefficacy of 2-hydroxy-4-(methylthio)butanoic acid (HMTBA) and dl-MET as Met sources in nursery pigs. Experiment 1 included 2 studies: 1 was 662 nursery pigs (Triumph 4 x PIC C22; initial BW 12.2 +/- 0.18 kg) allotted to 1 of 5 dietary treatments with TID Lys concentrations ranging from 1.10 to 1.50%; and the second study was 665 nursery pigs (Triumph 4 x PIC C22; initial BW 12.3 +/- 0.18 kg) allotted to 1 of 5 dietary treatments with TID SAA concentration ranging from 0.63 to 0.90%. In Exp. 2, 638 nursery pigs (Triumph 4 x PIC C22; initial BW 13.0 +/- 0.16 kg) were allotted to the same 5 SAA dietary treatments as in Exp. 1. In Exp. 3, 1,232 pigs (Triumph 4 x PIC C22; initial BW 11.0 +/- 0.30 kg) were allotted to 1 of 7 dietary treatments. The basal diet (diet 1) was supplemented with high concentrations of synthetic AA but no Met; this resulted in a dietary concentration of TID Lys of 1.30% and TID SAA of 0.50%. Diets 2 to 7 were the basal diet supplemented with 3 equimolar levels of HMTBA or dl-MET to provide TID SAA concentrations of 0.56, 0.62, and 0.68%, respectively. In Exp. 1, increasing TID Lys from 1.10 to 1.50% increased ADG (quadratic; P < 0.05) and improved G:F (linear; P < 0.002). The pooled data of Exp. 1 (SAA study) and Exp. 2 indicated that increasing TID SAA from 0.63 to 0.90% increased ADG (quadratic; P < 0.01) and improved G:F (quadratic; P < 0.01). Various methods of analyzing the growth response surface indicated that the optimal TID Lys concentration ranged from 1.28 to 1.32% for ADG (Exp. 1), and the optimal TID SAA concentration ranged from 0.73 to 0.77% for ADG and 0.80 to 0.83% for G:F (pooled Exp. 1 and 2), respectively. In Exp. 3, increasing TID SAA concentrations from 0.50 to 0.68% resulted in a linear improvement of ADG (P < 0.001), ADFI (P < 0.05), and G:F (P < 0.001). The best fit comparison of HMTBA and dl-MET was determined by the Schwartz Bayesian Information Criteria index, which indicated the average relative efficacy of HMTBA vs. dl-MET was 111%, with 95% confidence interval of 83 to 138%, within the range of TID SAA tested. Thus, the TID Lys and SAA requirements of modern lean-genotype pigs from 11- to 26-kg were greater than the 1998 NRC recommendations, and both HMTBA and dl-MET as Met sources can supply equimolar amounts of Met activity.

Estimation of the ideal ratio of true ileal digestible sulfur amino acids:lysine in 8- to 26-kg nursery pigs.

Four experiments were conducted to determine the ideal ratio of true ileal digestible (TID) sulfur AA to Lys (SAA:LYS) in nursery pigs at two different BW ranges using both DL-Met and 2-hydroxy-4-(methylthio)-butanoic acid (HMTBA) as Met sources. In Exp. 1, 1,549 nursery pigs (Triumph 4 x PIC Camborough 22; initial BW 8.3 +/- 0.08 kg) were allotted to one of nine dietary treatments. The basal diet (Diet 1) was a semicomplex corn-soybean meal-based diet (1.32% TID Lys) with no supplemental HMTBA or DL-Met (47.7% TID SAA:LYS). Diets 2 to 9 consisted of the basal diet supplemented with four equimolar levels of DL-Met or HMTBA (52.7, 57.7, 62.7, and 67.7% TID SAA:LYS). In Exp. 2, 330 nursery pigs (Triumph 4 x PIC Camborough 22; initial BW 11.4 +/- 0.10 kg) were allotted to one of nine dietary treatments. The basal diet (Diet 1) was a corn-soybean meal-based diet (1.15% TID Lys) with no supplemental HMTBA or DL-Met (49% TID SAA:LYS). Diets 2 to 9 consisted of the basal diet supplemented with four equimolar levels of DL-Met or HMTBA (54, 59, 64, and 69% TID SAA:LYS). In Exp. 3, 1,544 nursery pigs (Triumph 4 x PIC Camborough 22; initial BW 12.4 +/- 0.13 kg) were allotted to one of nine dietary treatments as in Exp. 2. In Exp. 4, 343 nursery pigs (Genetiporc; initial BW 12.8 +/- 0.56 kg) were allotted to one of six dietary treatments. The basal diet (Diet 1) was a corn-soybean meal-based diet (1.05% TID Lys) with no supplemental DL-Met (49% TID SAA:LYS). Diets 2 to 5 consisted of the basal diet supplemented with four levels of DL-Met (54, 59, 64, and 69% TID SAA:LYS), and Diet 6 was the basal diet supplemented with one equimolar level of HMTBA to satisfy 59% TID SAA:LYS ratio. In all experiments, increasing the TID SAA:LYS ratio resulted in quadratic improvements in ADG (P < or = 0.09) and G:F (P < or = 0.05). Three different methods were used to estimate the optimal TID SAA:LYS ratio for each experiment. The two-slope broken-line regression model, x-intercept value of the broken-line and quadratic curve, and 95% of upper asymptote across the four experiments indicated that the average optimal TID SAA:LYS ratios were 59.3, 60.1, and 57.7% for ADG and 60.6, 61.7, and 60.1% for G:F, respectively. Thus, the optimal TID SAA:LYS ratio for 8- to 26-kg pigs based on the average value of these three estimates was 59.0% for ADG and 60.8% for G:F.

Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.

UNLABELLED: Pretargeted radioimmunotherapy permits the administration of doses of 90Y five times higher than is possible with antibodies directly labeled with 90Yttrium (90Y). These high doses of 90Y introduced new issues for dosimetry that were not encountered in prior studies using conventional radioimmunotherapy. We have addressed these issues here and correlated dosimetry estimates with observed toxicity and tumor responses. METHODS: The pretargeted radioimmunotherapy (PRIT) system employed the antibody NR-LU-10 conjugated with streptavidin, a glycoprotein clearing agent and 90Y-DOTA-biotin. A single dose of 90Y was escalated to 140 mCi/m2. Indium-111(111In) (3-5 mCi) DOTA-biotin was co-injected for gamma camera imaging and dosimetry assessment. The effect of bremsstrahlung radiation from increasing 90Y activity levels with a constant dose of 111In was studied using a phantom. Patient images identified the intestinal tract and the kidneys as potential organs at risk of clinically significant radiation toxicity. A method of measuring the activity localized in the intestinal tract was developed, and S values were calculated to estimate intestinal wall dose from radioactivity present in the intestine. Intestinal, bone marrow and renal toxicity were observed. Coefficients were derived for correlating the relationships between observed intestinal and marrow toxicity and the estimated radiation absorbed doses. RESULTS: At an 90Y:111In ratio of 50:1, bremsstrahlung radiation accounted for 12% of the counts in the images. Grade IV diarrhea was observed in patients estimated to have received 6850-14,000 cGy to the large intestinal wall. The correlation coefficient of intestinal toxicity with absorbed dose was 0.64. Myelotoxicity (measured as grade of suppression of absolute neutrophil count) correlated better with marrow dose (r = 0.72) than with the whole body dose, (r = 0.44). Delayed renal toxicity was observed in two patients 8 and 11 months following therapy. Tumor response was seen in the two patients with the highest estimated dose to tumor, 4,000-6,000 cGy. CONCLUSION: Dosimetry is feasible using 111In as a tracer in the presence of high 90Y activity. The absorbed dose estimates derived in the PRIT schema correlated moderately well with clinically observed toxicity and response.

Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10.

A mouse-human chimeric monoclonal antibody (NR-LU-13), with the same pancarcinoma antigen recognition site as a previously studied murine monoclonal antibody (NR-LU-10), was radiolabeled with 186Re using a bifunctional chelate. Nine patients (ages 31-81 yr) with metastatic adenocarcinoma received 186Re NR-LU-13. A single intravenous dose of 42 mg NR-LU-13 labeled with 25 mCi/m2 (two patients) or 60 mCi/m2 (seven patients) was administered. Mean serum disappearance half-time values for the chimeric 186Re NR-LU-10). Fifty percent of the radiolabel was excreted in the urine by 6 days. Tumor localization was demonstrated by gamma camera imaging in seven of nine patients. The percent injected dose per gram in a single tumor biopsy specimen was 0.003% at 72 hr postinjection. Absorbed dose to bone marrow was 1.5 +/- 0.7 rads/mCi and resulted in reversible myelosuppression in five of six evaluable patients who received 60 mCi/m2: median WBC nadir = 2500/microliters; median platelet nadir = 85,500/microliters. Low grade fever, nausea, slight elevations of liver function tests and mild allergic reactions were seen in some patients. The chimeric antibody elicited low levels of anti-NR-LU-13 antibody in six of eight evaluable patients (75%), in contrast to NR-LU-10 which elicited higher levels of human anti-mouse antibody in all patients. This pilot study demonstrates the ability of the chimeric antibody to target tumors with reduced (but not absent) immunogenicity and delayed clearance relative to the murine antibody.

Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials.

Rhenium-186 is a beta-emitting radionuclide that has been studied for applications in radioimmunotherapy. Its 137 keV gamma photon is ideal for imaging the biodistribution of the immunoconjugates and for obtaining gamma camera data for estimation of dosimetry. Methods used for determining radiation absorbed dose are described. We have estimated absorbed dose to normal organs and tumors following administration of two different 186Re-labeled immunoconjugates, intact NR-LU-10 antibody and the F(ab')2 fragment of NR-CO-02. Tumor dose estimates in 46 patients varied over a wide range, 0.4-18.6 rads/mCi, but were similar in both studies. Accuracy of activity estimates in superficial tumors was confirmed by biopsy. Prediction of 186Re dosimetry from a prior 99mTc imaging study using a tracer dose of antibody was attempted in the NR-CO-02 (Fab')2 study. Although 99mTc was an accurate predictor of tumor localization and the mean predicted and observed radiation absorbed doses to normal organs compared favorably, 186Re dosimetry could not be reliably predicted in individual patients. The methods described nevertheless provide adequate estimates of 186Re dosimetry to tumor and normal organs.

Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.

Rhenium is a radionuclide with physical and chemical properties suitable for radioimmunotherapy. Two Phase I trials were carried out using 186Re-labeled murine monoclonal antibodies. Patients with refractory metastatic epithelial carcinoma received single doses of either 186Re-labeled intact NR-LU-10, a pancarcinoma antibody, 25-120 mCi/m2 (n = 15) or 186Re-labeled F(ab')2 fragment of NR-CO-02, an anti-CEA variant antibody, 25-200 mCi/m2 (n = 31). Prior to radioimmunotherapy, tumor localization of antibody was confirmed by 99mTc-labeled NR-LU-10 Fab or 99mTc-labeled NR-CO-02 F(ab')2 imaging. Dose-limiting myelosuppression was observed at 120 mCi/m2 following 186Re-NR-LU-10 intact antibody and at 150 mCi/m2 following NR-CO-02 F(ab')2 fragment in heavily pretreated patients. In patients with minimal prior therapy, a maximum tolerated dose for NR-CO-02 F(ab')2 was not reached by 200 mCi/m2. Non-marrow toxicity was minimal. Human anti-mouse antibody developed in all patients receiving intact NR-LU-10, and in 86% patients receiving F(ab')2 NR-CO-02. One patient treated with 186Re NR-CO-02 achieved a partial response. We conclude that 186Re-labeled antibody can be safely administered with significant toxicity limited to marrow.